BR112022014493A2 - Célula de cho que expressa heterodímeros de il-15 - Google Patents

Célula de cho que expressa heterodímeros de il-15

Info

Publication number
BR112022014493A2
BR112022014493A2 BR112022014493A BR112022014493A BR112022014493A2 BR 112022014493 A2 BR112022014493 A2 BR 112022014493A2 BR 112022014493 A BR112022014493 A BR 112022014493A BR 112022014493 A BR112022014493 A BR 112022014493A BR 112022014493 A2 BR112022014493 A2 BR 112022014493A2
Authority
BR
Brazil
Prior art keywords
cho cell
heterodimers
cell expressing
heterodimer
producing
Prior art date
Application number
BR112022014493A
Other languages
English (en)
Inventor
Gabriel Richard
Jostock Thomas
JOZEFCZUK Justyna
Ulrich LOHRIG Urs
Aurélien Pons Alexandre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022014493A2 publication Critical patent/BR112022014493A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

CÉLULA DE CHO QUE EXPRESSA HETERODÍMEROS DE IL-15. A presente invenção refere-se ao heterodímero de IL-15/IL-15Ra produzido em uma linhagem de célula de CHO e método para produzir o heterodímero e método de tratamento com o uso do heterodímero.
BR112022014493A 2020-02-05 2021-01-29 Célula de cho que expressa heterodímeros de il-15 BR112022014493A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
BR112022014493A2 true BR112022014493A2 (pt) 2022-09-20

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014493A BR112022014493A2 (pt) 2020-02-05 2021-01-29 Célula de cho que expressa heterodímeros de il-15

Country Status (21)

Country Link
US (1) US20210244821A1 (pt)
EP (1) EP4100425A1 (pt)
JP (2) JP2022522566A (pt)
KR (1) KR20220137651A (pt)
CN (1) CN115023436A (pt)
AR (1) AR121261A1 (pt)
AU (1) AU2021215893A1 (pt)
BR (1) BR112022014493A2 (pt)
CA (1) CA3168469A1 (pt)
CL (2) CL2022002094A1 (pt)
CO (1) CO2022010860A2 (pt)
CR (1) CR20220367A (pt)
DO (1) DOP2022000156A (pt)
EC (1) ECSP22060286A (pt)
IL (1) IL295278A (pt)
JO (1) JOP20220174A1 (pt)
MX (1) MX2022009611A (pt)
PE (1) PE20221509A1 (pt)
TW (1) TW202142558A (pt)
UY (1) UY39062A (pt)
WO (1) WO2021156720A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
KR101577849B1 (ko) 2008-08-22 2015-12-15 마그나 시팅 인크. 감소된 백래쉬를 갖는 디스크 리클라이너
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
PT2619229T (pt) 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
AU2013334610B2 (en) * 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
AU2015254913B2 (en) 2014-04-29 2018-05-17 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
AU2015366795B2 (en) * 2014-12-19 2020-12-17 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex and use thereof
US20190169253A1 (en) * 2016-08-01 2019-06-06 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
BR112019007920A2 (pt) * 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
CA3046120A1 (en) * 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
SG11202007240QA (en) * 2018-02-02 2020-08-28 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物

Also Published As

Publication number Publication date
JP2023145622A (ja) 2023-10-11
AU2021215893A1 (en) 2022-08-25
CR20220367A (es) 2022-08-30
CL2023002447A1 (es) 2024-03-15
CA3168469A1 (en) 2021-08-12
CL2022002094A1 (es) 2023-03-10
UY39062A (es) 2021-09-30
US20210244821A1 (en) 2021-08-12
CO2022010860A2 (es) 2022-08-19
AR121261A1 (es) 2022-05-04
IL295278A (en) 2022-10-01
WO2021156720A1 (en) 2021-08-12
MX2022009611A (es) 2022-11-07
JP2022522566A (ja) 2022-04-20
KR20220137651A (ko) 2022-10-12
CN115023436A (zh) 2022-09-06
DOP2022000156A (es) 2022-10-16
PE20221509A1 (es) 2022-10-04
TW202142558A (zh) 2021-11-16
ECSP22060286A (es) 2022-09-30
JOP20220174A1 (ar) 2023-01-30
EP4100425A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
BR112022014493A2 (pt) Célula de cho que expressa heterodímeros de il-15
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
MX2018002293A (es) Sistemas y métodos para las llamadas variantes de alta precisión.
CL2011002019A1 (es) Metodo y sistema de computador para proveer archivos fuente a un visor de documentos que opera en un computador cliente.
BR112016007211A2 (pt) composição contendo um poluiretano termoplástico, em que o poliuretano termoplástico é produzido a partir de um diisocianato, de um poliol que contém um poliol a e um poliol b, e de um extensor de cadeia, mistura, uso da composição, método para produção da composição e poliuretano termoplástico
PE20160103A1 (es) Panel de construccion que tiene una fuerza de fijacion mejorada y metodo para la elaboracion del mismo
BRPI0801188B8 (pt) cimento ósseo de polimetilmetacrilato
BR112017018103A2 (pt) partículas fluorescentes com uma camada protetora e um método para a produção das partículas fluorescentes com a camada protetora
BR112015022858A2 (pt) filme multicamadas polimérico e métodos para produzir o mesmo
CO2022013055A2 (es) Tafoxiparina para el tratamiento de la preeclampsia
BR112013005247A2 (pt) sistemas e métodos para análise de documentos
BR112018004619A2 (pt) vidro de segurança e método para a obtenção
ECSP21063501A (es) Métodos para el control de sigatoka negra en bananas usando aceite de pongamia y sus formulaciones
BR112019001186A2 (pt) método de fazer partículas em forma de haste para uso como aditivo anti-refluxo
BR112023018344A2 (pt) Composições de cimento, e métodos das mesmas
PL130737U1 (pl) Układ sortujący
PH12017500729A1 (en) Construction panel having improved fixing strenght
BR112015025549A2 (pt) anticorpo contra o receptor do fator de crescimento epidérmico
AR102232A1 (es) Partición para una estructura de construcción con resistencia a la deformación mejorada
BR112022008652A2 (pt) Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção
MX2016005009A (es) Moldura que se ilumina para un vehiculo.
Gaveika UNIFIED LAWYERS EXAMINATION, FOR AND AGAINST
CO2023001066A2 (es) Anticuerpos anti- αlfa-4-βeta-7
BR112022027030A2 (pt) Composição, processo e uso